Drug Competition Enhancement Act
Sponsor

- Conservative Groups$79,418k
- Climate & Environment$24,960k
Full profile: /officials/C001056
Source: Congress.gov · FEC
Cosponsors (3)
Members who have signed on to support this bill since introduction. Source: Congress.gov.
3 cosponsors on record at Congress.gov. The named list is syncing into Govwatch and will appear here shortly — view on Congress.gov in the meantime.
Latest Action
The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →
Placed on Senate Legislative Calendar under General Orders. Calendar No. 43.
2025-04-10
Source: Congress.gov
Committee Activity
Currently in
- Senate Committee on the JudiciaryReported By · 2025-04-10
Previously
- Senate Committee on the JudiciaryMarkup By · 2025-04-03
- Senate Committee on the JudiciaryReferred To · 2025-03-13
Plain-English Summary
Drug Competition Enhancement Act This bill prohibits product hopping by drug manufacturers and authorizes the Federal Trade Commission (FTC) to enforce this prohibition. Generally, product hopping describes a situation where, when the patents on a reference drug (or biological product) expire, the manufacturer switches to a follow-on product that is covered by a later-expiring patent. Under this bill, a follow-on product is a modified version of the reference drug that has an indication (what the drug is used for) that is identical or substantively similar to an indication of the reference drug. The bill establishes a presumption that product hopping has occurred when a reference drug manufacturer, after receiving notice that the Food and Drug Administration has received an application to market a competing generic (or biosimilar) version, takes certain actions such as withdrawing the reference drug from the market and selling a follow-on product. A drug manufacturer may rebut these presumptions by demonstrating that its conduct was not intended to limit competition. The bill makes product hopping an unfair method of competition and provides for enforcement by the FTC. If the FTC has reason to believe a manufacturer has violated or is about to violate this prohibition on product hopping, the FTC may institute an administrative proceeding or bring suit in federal court to stop the manufacturer’s action and seek equitable remedies, including disgorgement of unjust profits or paying restitution to those harmed.
Plain-English rewrite of the Congressional Research Service summary published on Congress.gov. Cached and reviewed.
Subjects
Related legislation
Bills by the same sponsor or covering overlapping subjects.
- SRES948A resolution commending and congratulating Texas A&M University for 150 years of service to the State of Texas and the United States.Introduced · 2026-09-30
- S5677A bill to establish the Lone Star Coastal National Recreation Area to conserve, protect, and promote the economic benefits of the natural, cultural, and recreational resources of the Upper and Middle Texas Gulf Coast as a unit of the National Park System.Referred to Committee · 2026-09-30
- S5543STRONGER ActReferred to Committee · 2026-09-24
- S388Promoting Resilient Buildings ActReported by Committee · 2026-09-15